Ubs Oconnor LLC Aligos Therapeutics, Inc. Transaction History

Ubs Oconnor LLC

  • $1.46 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
BUY
$0.35 - $1.07 $175,000 - $535,000
500,000 Added 100.0%
1,000,000 $350,000
Q1 2024

May 15, 2024
BUY
$0.64 - $1.13 $320,000 - $565,000
500,000 New
500,000 $490,000

Others Institutions Holding ALGS

# of Institutions
3
Shares Held
253K
Call Options Held
0
Put Options Held
0
View Full List

About Aligos Therapeutics, Inc.

ALGS Quotes by TradingView
  • Ticker ALGS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,717,000
  • Market Cap $751M
  • Description
  • Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...
More about ALGS
Track This Portfolio

Track Ubs Oconnor LLC Portfolio

Follow Ubs Oconnor LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email